Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Under the Medicaid system, individual ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its GLP-1 stalwarts Ozempic and Wegovy is more of a mixed bag. For the ...

GLP-1 agonist medications have gained significant attention, especially for their role in weight management and type 2 diabetes treatment. While these medications have been around for nearly 20 ...

That’s why Amazon shoppers are turning to this affordable GLP-1 supplement that helps curb cravings. This GLP-1 Supplement on Amazon is highly effective in assisting with the natural production ...

Increased adoption of GLP-1 drugs, rising catastrophic claims and other cost pressures are driving employer-sponsored health insurance costs to new heights. Current projections range from 7% to 8% ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

GLP-1 medications like Ozempic and Wegovy are sprinting their way into the fitness community, changing how athletes approach training, nutrition, and performance. Here’s what’s really going ...

Share on Pinterest A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like Ozempic. FreshSplash/Getty Images A new study shows a 50% ...

The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and gastrointestinal endoscopies, according to updated guidance from five ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...